Text resize



Phone Icon


Observational statin study in ASPREE participants

Jul 6, 2021

Statins may prevent heart attacks and strokes but may not prolong life free of disability



PRESS RELEASE July 2, 2020

A new observational study shows the first-line cholesterol-lowering drugs known as statins are associated with fewer heart attacks and strokes, but not associated with a prolonged life free of physical disability or dementia in healthy older people.

The study was a collaboration between researchers from the University of Tasmania’s Menzies Institute for Medical Research and ASPREE researchers in the United States and Australia.

Study data was collected from 18,096 ASPREE (ASPirin in Reducing Events in the Elderly) trial participants, mostly aged 70 years and older. ASPREE was a large-scale randomised clinical trial of low-dose aspirin, led by the Berman Center for Outcomes and Clinical Research in the United States and Monash University in Australia. A total of 19,114 community dwelling participants, who were mostly 70 years of age or older, with no known cardiovascular disease, dementia or significant physical disability initially, were enrolled in the ASPREE trial from 2010 through 2014.

Compared with ASPREE participants who were not taking statins when recruited, those who reported statin use at enrolment (31%, N= 5,629) were observed to have fewer heart attacks and strokes (4.6% vs. 3.3%) and persistent physical disability (2.2% vs. 1.9%) over an average of 4.7 years. Physical disability was possibly affected by reduced cardiovascular events.

In contrast, no differences were seen for deaths, dementia and cancer events, nor for the length of disability-free life. There were no age and gender differences in these results, the researchers report.

Woman with dark hair, glasses in a white coat, in front of a white background, smiles at the camera
Above: Lead author, Dr Zhen (Lucy) Zhou

The authors say the findings are observational only and underscore the importance of STAREE (Statins in Reducing Events in the Elderly), a clinical trial of statins in older adults led by Monash University.

Australian ASPREE Chief Investigator, general practitioner and study co-author, Professor Mark Nelson, said comprehensive health data in the ASPREE trial has enabled researchers to investigate a range of factors that may affect the healthy older adults, including statin use.

“GPs have a dilemma.  As their patient gets older their risk of heart and stroke gets higher.  Should they give them medications such as statins to protect them even if they have no symptoms of disease? There is a paucity of clinical trials in the elderly to indicate what is the best thing to do.”

“This study suggests that there may be a cardiovascular protective effect of statins in the elderly but this needs to be established in a randomised controlled trial such as the STAREE trial currently being undertaken in Australian general practice.”

Lead author, Dr Zhen Zhou, said that the study findings suggest that statin therapy may have varying benefits on different health outcomes in healthy older people.

“In the absence of evidence, these findings support the current clinical practice guidelines that statin therapy in the healthy elderly needs to be considered on an individualised basis.”

An observational follow-up study of ASPREE participants named ASPREE-XT (eXTension) is underway that allows ASPREE researchers to study participants’ health outcomes over the longer term.

“The Australian STAREE study led by Monash University, the world’s largest primary prevention trial of statins in the elderly, should inform clinicians on whether giving daily doses of a statin to healthy elderly Australians will help them live longer and healthier,” Dr Zhou said.

The article was published in the Journal of the American College of Cardiology on June 30, 2020.


Other Articles

CliniciansObservational statin study in ASPREE participants